KBC Group NV cut its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 93.8% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 3,750 shares of the company's stock after selling 56,764 shares during the period. KBC Group NV's holdings in CRISPR Therapeutics were worth $128,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Wood Tarver Financial Group LLC purchased a new position in CRISPR Therapeutics in the fourth quarter valued at $30,000. Ameriflex Group Inc. purchased a new position in CRISPR Therapeutics in the fourth quarter valued at $36,000. NBC Securities Inc. increased its holdings in CRISPR Therapeutics by 156,300.0% in the first quarter. NBC Securities Inc. now owns 1,564 shares of the company's stock valued at $53,000 after buying an additional 1,563 shares in the last quarter. GF Fund Management CO. LTD. purchased a new position in CRISPR Therapeutics in the fourth quarter valued at $71,000. Finally, GAMMA Investing LLC increased its holdings in CRISPR Therapeutics by 8,146.2% in the first quarter. GAMMA Investing LLC now owns 4,288 shares of the company's stock valued at $146,000 after buying an additional 4,236 shares in the last quarter. 69.20% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
A number of research firms have recently commented on CRSP. Barclays cut their target price on shares of CRISPR Therapeutics from $56.00 to $42.00 and set an "equal weight" rating for the company in a research note on Friday, May 9th. Needham & Company LLC reissued a "buy" rating and set a $81.00 target price on shares of CRISPR Therapeutics in a research note on Thursday, June 26th. Wall Street Zen raised shares of CRISPR Therapeutics to a "sell" rating in a research note on Friday, May 16th. HC Wainwright reissued a "buy" rating and set a $65.00 target price on shares of CRISPR Therapeutics in a research note on Friday, June 27th. Finally, The Goldman Sachs Group lowered their price target on shares of CRISPR Therapeutics from $53.00 to $47.00 and set a "neutral" rating on the stock in a research report on Thursday, May 8th. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating and ten have issued a buy rating to the company's stock. According to data from MarketBeat.com, CRISPR Therapeutics presently has a consensus rating of "Hold" and an average target price of $71.75.
View Our Latest Analysis on CRSP
CRISPR Therapeutics Stock Down 1.9%
CRISPR Therapeutics stock opened at $51.19 on Tuesday. CRISPR Therapeutics AG has a 52-week low of $30.04 and a 52-week high of $63.68. The firm has a fifty day moving average of $40.95 and a 200-day moving average of $40.81. The firm has a market capitalization of $4.42 billion, a P/E ratio of -11.33 and a beta of 1.82.
CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last announced its earnings results on Tuesday, May 6th. The company reported ($1.58) earnings per share for the quarter, missing the consensus estimate of ($1.27) by ($0.31). CRISPR Therapeutics had a negative net margin of 1,023.64% and a negative return on equity of 20.08%. During the same quarter in the previous year, the company earned ($1.43) earnings per share. The firm's quarterly revenue was up 71.6% on a year-over-year basis. On average, research analysts expect that CRISPR Therapeutics AG will post -5.16 EPS for the current fiscal year.
Insider Activity
In other news, insider Naimish Patel sold 3,932 shares of the firm's stock in a transaction dated Thursday, May 29th. The shares were sold at an average price of $35.94, for a total value of $141,316.08. Following the transaction, the insider directly owned 6,068 shares in the company, valued at approximately $218,083.92. This trade represents a 39.32% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 4.10% of the company's stock.
About CRISPR Therapeutics
(
Free Report)
CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.
Featured Articles
Want to see what other hedge funds are holding CRSP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider CRISPR Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CRISPR Therapeutics wasn't on the list.
While CRISPR Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
